Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy
View Patent ↗The present invention concerns a method of therapeutic prevention and treatment of a heart disease chosen from cardiac insufficiency and heart failure including the administration of an essential fatty acid containing a mixture of eicosapentaenoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA), either alone or in combination with another therapeutic agent.
1. A method for treating a heart disease selected from the group consisting of chronic cardiac insufficiency and chronic heart failure, the method comprising administering to a patient in need thereof a therapeutically effective amount of essential fatty acids comprising a mixture of eicosapentaenoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA) wherein the content of EPA+DHA in the mixture is higher than 25% by weight, as the sole therapeutic agent for the treatment of the chronic cardiac insufficiency or chronic heart failure.
2. The method according to claim 1 , wherein the content of EPA+DHA in the mixture is from about 30% to about 100% by weight.
3. The method according to claim 1 , wherein the content of EPA+DHA in the mixture is about 85% by weight.
4. The method according to claim 1 , wherein the essential fatty acids are orally administered at a dose of from about 0.7 g to about 1.5 g daily.
5. The method according to claim 1 , wherein the patient is a person older than 60 years.
6. A method for reducing acute heart failure events in a patient having heart disease, the method comprising administering to a patient having a heart disease selected from the group consisting of chronic cardiac insufficiency and chronic heart failure, essential fatty acids comprising a mixture of eicosapentaenoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA) wherein the content of EPA+DHA in the mixture is higher than 25% by weight, in an amount effective to reduce acute heart failure events in the patient, wherein the essential fatty acids are the sole therapeutic agent for the treatment of the chronic cardiac insufficiency or chronic heart failure.
7. The method according to claim 6 , wherein the content of EPA+DHA in the mixture is from about 30 to about 100% by weight.
8. The method according to claim 6 , wherein the content of EPA+DHA in the mixture is about 85% by weight.
9. The method according to claim 6 , wherein the essential fatty acids are administered orally at a dosage from about 0.7 g to about 1.5 g daily.
10. The method according to claim 6 , wherein the patient is a person older than 60 years.
11. A method for reducing acute heart failure events in a patient having heart disease, the method comprising administering to a patient having a heart disease selected from the group consisting of chronic cardiac insufficiency and chronic heart failure, oral dosage forms comprising 1 g of oil containing ethyl esters of polyunsaturated fatty acids comprising omega-3 fatty acids comprising a mixture of eicosapentaenoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA) wherein the content of EPA+DHA in the oil is greater than 25% by weight, in an amount effective to reduce acute heart failure events in the patient, wherein the essential fatty acids are the sole therapeutic agent for the treatment of the chronic cardiac insufficiency or chronic heart failure.
12. The method according to claim 11 , wherein the content of EPA+DHA in the mixture is from about 30 to about 100% by weight.
13. The method according to claim 11 , wherein the content of EPA+DHA in the mixture is about 85% by weight.
14. The method according to claim 11 , wherein the patient is a person older than 60 years.